Roche Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema

Phase 3vamikibartPositive

AI Analysis

Summary

Roche announced one-year Phase III data from the MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with sham procedure for uveitic macular edema treatment.

Clinical Trial Data

Phase

Phase III

Outcome Details

One-year data from Phase III MEERKAT and SANDCAT studies presented

Importance:6/10

Sentiment:

0.50

Phase_3_datavamikibartuveitic_macular_edemaRocheclinical_trial

Related Companies

$RHHBY

Read the original article

Published by Drugs.com Clinical Trial Results on October 10, 2026 1:10 AM

Read Original